Olympus Duodenoscope Infection Lawsuit

Between 2013 and 2024, contaminated Olympus duodenoscopes infected hundreds of patients at hospitals across the United States. At least 35 people died. The infections were caused by drug-resistant bacteria that no antibiotic could reliably kill. The patients had gone into the hospital for routine diagnostic procedures–gallstone evaluations, pancreatic biopsies, bile duct imaging–and came out with infections that would destroy their organs, land them in intensive care for months, or kill them outright.

The remarkable part is not that it happened. Medical devices fail. Infections occur. What makes the Olympus duodenoscope litigation extraordinary is that the company knew. Olympus knew its scopes could not be adequately cleaned. Olympus knew that bacteria were surviving the sterilization process and spreading from patient to patient. Olympus knew that people were dying. And for years, the company did almost nothing.

This page explains what went wrong, why it went wrong, and the legal options available to patients and families harmed by contaminated Olympus scopes. It is long. It is detailed. It is written for people who want to understand not just the claims being filed, but the science, the regulatory failures, and the corporate decisions that turned a solvable engineering problem into a public health catastrophe.

What Is a Duodenoscope?

A duodenoscope is a flexible, lighted tube that physicians thread down a patient’s throat, through the stomach, and into the duodenum—the first section of the small intestine. From there, the scope allows access to the bile ducts, the pancreatic duct, and the surrounding anatomy. The procedure that uses it is called an ERCP: endoscopic retrograde cholangiopancreatography.

ERCP is one of the most technically demanding procedures in gastroenterology.  Our law firm has had more than our fair share of medical malpractice lawsuits involving ERCPs.

The procedure is used to diagnose and treat conditions involving the bile ducts and pancreas, such as gallstones lodged in the common bile duct, strictures, tumors, and chronic pancreatitis. When performed correctly with sterile equipment, it is invaluable. Approximately 500,000 to 700,000 ERCPs are performed in the United States each year.

The duodenoscope differs from a standard endoscope in one critical respect. It has a small mechanical component at its tip called the elevator mechanism. This tiny lever allows the physician to manipulate guidewires, stents, and other instruments during the procedure. Without it, ERCP would not be possible.

The elevator mechanism is also the source of the problem.

The Design Defect: Why These Scopes Cannot Be Cleaned

The elevator channel is a small, enclosed cavity with intricate crevices, seams, and moving parts. It sits at the distal tip of the duodenoscope—the end that contacts the patient’s internal tissue, bile, pancreatic fluid, and blood. After a procedure, this channel is contaminated with biological material. The question is whether it can be adequately decontaminated before the next patient.

The answer, according to years of outbreak data and peer-reviewed research, is clearly no. Just not reliably, anyway. Not even when hospitals follow the manufacturer’s cleaning instructions to the letter.

Here is why.  Standard sterilization relies on chemical disinfectants reaching every surface of the device. But the elevator channel is not a smooth, open cavity. It contains microscopic gaps between the elevator lever and its housing. It has O-rings, seals, and joints that trap fluid and debris. The geometry of the channel makes it physically impossible for brushes, detergents, or high-level disinfectants to reach every contaminated surface. Once a biofilm establishes itself inside the elevator channel, removing it is like trying to scrub mold out of grout with a toothbrush. The geometry defeats the effort.

Bacteria that survive the cleaning process do not simply sit on the surface waiting to be wiped away. They form biofilms, which are structured colonies of microorganisms that adhere to surfaces and secrete a protective matrix. Once a biofilm establishes itself inside the elevator channel, it becomes extraordinarily difficult to remove. Standard chemical disinfection does not penetrate the biofilm effectively. The bacteria persist. So the next patient who undergoes ERCP with that scope is exposed to whatever organisms the previous patient was carrying.

This is not a cleaning failure by hospitals. It is a design failure by Olympus. The device was engineered in a way that makes adequate reprocessing impossible under real-world conditions.

 

What Are CRE and Other Drug-Resistant Bacteria?

The bacteria most commonly linked to duodenoscope infections belong to a family called Enterobacteriaceae, organisms that normally live in the human gut. The most dangerous strains are those that have developed resistance to carbapenem antibiotics, a class of drugs typically reserved as a last resort for serious infections. These resistant strains are called carbapenem-resistant Enterobacteriaceae, or CRE.

CRE infections are not like ordinary bacterial infections. They stubbornly do not respond to most antibiotics. When CRE enters the bloodstream, the mortality rate approaches a depressing 50 percent. Patients who survive often endure weeks or months in intensive care, multiple surgeries, and permanent organ damage.

Other drug-resistant organisms have also been linked to contaminated duodenoscopes, including:

• Pseudomonas aeruginosa — a bacterium associated with hospital-acquired pneumonia and bloodstream infections
• Klebsiella pneumoniae — a leading cause of CRE outbreaks in healthcare settings
• Escherichia coli (E. coli) — strains that have acquired resistance genes and become difficult to treat
• Enterococcus — organisms that can cause endocarditis and other serious infections

These are not exotic pathogens. They are bacteria that exist in every hospital. What makes them deadly is the combination of drug resistance and a delivery mechanism — the contaminated duodenoscope — that deposits them directly into the bile ducts and bloodstream of vulnerable patients.

The Outbreak History: How Many People Were Infected?

The contaminated duodenoscope problem did not emerge overnight. It unfolded over more than a decade, with outbreaks occurring at hospitals across the country, often without public disclosure, often without the hospitals themselves understanding the source.

Here is what we know.

Virginia Mason Medical Center (Seattle, 2013)

In 2013, Virginia Mason Medical Center in Seattle identified a cluster of patients who had developed CRE infections after undergoing ERCP. The hospital eventually traced the infections to a single Olympus duodenoscope. Thirty-five patients were infected. Eleven died.

This was one of the first major outbreaks linked specifically to duodenoscope contamination. The hospital reported its findings to the FDA and to Olympus. Both were now on notice.

Ronald Reagan UCLA Medical Center (Los Angeles, 2015)

In early 2015, UCLA disclosed that more than 170 patients had been exposed to CRE-contaminated duodenoscopes. At least seven patients were confirmed infected. Two died.

The UCLA outbreak made national news. It was the moment when the duodenoscope problem became impossible to ignore. Congressional hearings followed. The FDA issued a safety communication. Olympus issued updated reprocessing instructions. But the infections did not stop.

Cedars-Sinai Medical Center (Los Angeles, 2015)

Within weeks of the UCLA disclosure, Cedars-Sinai reported its own outbreak linked to contaminated Olympus duodenoscopes. Four patients were infected with CRE.

Advocate Lutheran General Hospital (Chicago, 2016)

An outbreak at Advocate Lutheran General Hospital in suburban Chicago infected dozens of patients. The hospital did not publicly disclose the full scope of the contamination for months.

Additional Outbreaks

Outbreaks have been reported or suspected at hospitals in:

• North Carolina
• Pennsylvania
• Colorado
• Massachusetts
• New Jersey
• Florida

The true number of patients infected by contaminated duodenoscopes is unknown. Many hospitals did not conduct surveillance. Many infections were attributed to other causes. Many patients were never told that their ERCP may have exposed them to a contaminated device.

A 2015 analysis estimated that approximately 350,000 patients per year undergo ERCP with reusable duodenoscopes. Even a contamination rate of less than one percent would translate into thousands of infections annually. And the actual contamination rate, based on culture studies of properly reprocessed scopes, appears to be far higher than one percent.

What Did Olympus Know, and When Did They Know It?

This is the question at the heart of every duodenoscope lawsuit. And while these lawsuits are just getting started, our lawyers think from the evidence we have already, Olympus is in trouble.

Olympus is a Japanese multinational that dominates the global market for gastrointestinal endoscopes. The company holds approximately 70 percent of the worldwide market share for these devices. In the United States, Olympus duodenoscopes were and remain the most commonly used devices for ERCP.

Internal documents, FDA communications, and litigation discovery have revealed that Olympus was aware of contamination risks associated with its duodenoscopes long before the major outbreaks became public.

2012: European Safety Signals

Reports from European hospitals indicated that Olympus duodenoscopes were linked to patient infections even when cleaned according to the manufacturer’s instructions. Olympus received these reports and did not take meaningful corrective action.

2013: The Virginia Mason Outbreak

After the Seattle outbreak, Virginia Mason notified Olympus directly. The hospital’s infection control team explained that the design of the elevator channel made adequate cleaning impossible. Olympus did not issue a recall. It did not modify the device design. It did not warn other hospitals.

2014-2015: Internal Acknowledgment

Documents produced in litigation suggest that Olympus engineers and executives understood the scope of the contamination problem but delayed action because of the financial and reputational costs of a recall or redesign.

2015: FDA Safety Communication

In February 2015, following the UCLA outbreak, the FDA issued a safety communication acknowledging that duodenoscopes posed infection risks even when properly reprocessed. The agency did not order a recall. It did not ban the devices. It suggested that hospitals consider additional sterilization measures—measures that were never validated and that many hospitals could not implement.

2016: Olympus Updates Reprocessing Instructions

Olympus issued revised cleaning instructions that acknowledged the complexity of the elevator channel and recommended more aggressive reprocessing protocols. Critics noted that the company had effectively admitted the original instructions were inadequate—instructions that had been in use for years while patients were being infected.

2022: FDA Warning Letter

In November 2022, the FDA issued a warning letter to Olympus subsidiary Aizu Olympus Co., Ltd., citing multiple violations of quality system regulations at a manufacturing facility in Japan. The violations included:

• Failure to adequately validate product designs
• Failure to document and test manufacturing processes
• Failure to establish written procedures for reporting adverse events

These were not minor paperwork issues. They were systemic failures that went to the core of whether Olympus was manufacturing safe medical devices.

2025: FDA Import Alerts

In June 2025, the FDA issued import alerts blocking 58 Olympus products manufactured at the Aizu facility from entering the United States. The alerts cited ongoing failures to comply with FDA requirements.

The timeline speaks for itself. Olympus knew about the contamination risk for more than a decade. The company made incremental changes—revised instructions, updated designs, voluntary recalls of specific accessories—while the fundamental problem persisted. Patients continued to be infected. Patients continued to die.

The FDA’s Role: Regulatory Failure

Olympus bears primary responsibility for the harm caused by its defective devices. But the FDA’s performance in this episode was also a failure.

The agency knew about duodenoscope contamination risks as early as 2013. Between 2013 and 2015, the FDA received hundreds of adverse event reports involving duodenoscope-related infections. The agency did not act aggressively. It sat on its hands.  It did not order recalls. It did not require design changes. It issued safety communications that shifted the burden to hospitals and continued to allow the devices to be sold.

Part of the problem is structural. Duodenoscopes entered the market through the FDA’s 510(k) clearance pathway, which allows medical devices to be sold without clinical trials if they are “substantially equivalent” to devices already on the market. The 510(k) process is faster and cheaper than premarket approval, but it does not require manufacturers to prove that a device is safe but only that it is similar to something that was already cleared. It would be hard to impress upon you how many mass tort lawsuits begin with “the product entered the market through the backdoor 510(k) process.”

When safety problems emerged, the FDA had limited tools to force Olympus to act. The agency could issue warning letters. It could negotiate with the company. It could refer cases to the Department of Justice for potential criminal prosecution. What it could not do, or chose not to do, was pull the devices off the market quickly and decisively.

The result was years of preventable infections while the FDA and Olympus engaged in a slow-motion regulatory dance.

 

The Legal Landscape: What Claims Are Being Filed?

Patients and families harmed by contaminated Olympus duodenoscopes have filed lawsuits in federal and state courts across the country. The claims generally fall into three categories.

1. Design Defect

The core allegation is that Olympus duodenoscopes were defectively designed because their elevator mechanism could not be adequately cleaned using available reprocessing methods. A properly designed device would allow for complete sterilization. The Olympus scopes did not.

Design defect claims do not require proof that the manufacturer was negligent. They require proof that the device was unreasonably dangerous as designed and that a safer alternative design was feasible.

2. Failure to Warn

Olympus knew or should have known (we think knew) that its duodenoscopes posed contamination risks that persisted even when hospitals followed the company’s own reprocessing instructions. The company had a duty to warn physicians, hospitals, and patients of these risks. It failed to do so adequately.

Failure-to-warn claims are often the most powerful in medical device litigation because they focus on what the manufacturer knew and when. Internal documents showing that Olympus understood the contamination problem but delayed warnings are central to these claims.

3. Manufacturing Defect

Some claims allege that specific Olympus devices were defectively manufactured, deviating rom the company’s own design specifications in ways that made them more likely to harbor bacteria. The FDA’s findings regarding the Aizu facility support allegations that manufacturing quality control was inadequate.

Verdicts and Settlements

To date, Olympus has settled numerous individual cases for confidential amounts. The company has not agreed to a global settlement that would resolve all pending claims. Litigation continues in both federal and state courts.

Because many cases have settled confidentially, the full picture of compensation is not publicly available. However, given the severity of the injuries—deaths, prolonged ICU stays, permanent organ damage, loss of earning capacity—settlement values in serious cases are substantial.

Who Can File an Olympus Duodenoscope Lawsuit?

If you or a family member underwent an ERCP or other procedure involving an Olympus duodenoscope and subsequently developed an infection, you may have a claim. The key questions are:

1. Was an Olympus duodenoscope used during the procedure? Hospital records should document the specific device used. If the records are unclear, your medical team or the hospital’s risk management department may be able to confirm.
2. Did you develop an infection within 90 days of the procedure? The most common pattern involves infections that appear within days to weeks after ERCP. Infections that required hospitalization, IV antibiotics, ICU admission, or surgery are most likely to support a claim.
3. Was the infection caused by a drug-resistant organism? Infections involving CRE, Pseudomonas, or other resistant bacteria are strongly associated with duodenoscope contamination. Culture results from the hospital should identify the organism.
4. Did the infection cause significant harm? Patients who died, suffered prolonged hospitalization, required organ transplants, or experienced permanent disability have the strongest claims. Patients who developed infections that resolved quickly with antibiotics may have weaker claims, though every case is different.
5. Is the statute of limitations still open? Each state has its own deadline for filing a medical device lawsuit. The clock typically begins when the patient knew or should have known that the device caused the injury. Because many patients were not told about the contamination risk, the limitations period may be extended under the discovery rule. An attorney can evaluate whether your claim is timely.

What Compensation Can Victims Recover?

Patients harmed by contaminated Olympus duodenoscopes can seek compensation for:

• Medical expenses — hospital stays, surgeries, medications, rehabilitation, and ongoing care
• Lost wages and earning capacity — income lost during illness and any permanent reduction in the ability to work
• Pain and suffering — the physical pain, emotional distress, and diminished quality of life caused by the infection and its treatment
• Wrongful death damages — if a family member died as a result of a duodenoscope infection, surviving family members may recover damages for funeral expenses, loss of financial support, and loss of companionship

In cases involving particularly egregious corporate conduct, juries may also award punitive damages—compensation designed not to reimburse the plaintiff but to punish the defendant and deter similar conduct in the future. The evidence that Olympus knew about contamination risks and delayed action could support punitive damages in appropriate cases.

A Patient’s Story: What These Infections Actually Mean

Statistics do not convey what it is like to contract a CRE infection from a routine medical procedure. A patient’s story does.

Consider a 58-year-old woman, a retired schoolteacher, a grandmother, who goes into the hospital for evaluation of a suspected gallstone. The procedure is ERCP. It takes less than an hour. She is told she can go home the same day.

Three days later, she develops a fever. Then chills. Then confusion. Her daughter brings her to the emergency room. Blood cultures come back positive for carbapenem-resistant Klebsiella pneumoniae. She is admitted to the ICU.

Over the next six weeks, she undergoes three surgeries. Her bile ducts are infected. Her bloodstream is infected. Her kidneys begin to fail. The infectious disease team cycles through every available antibiotic. Nothing works reliably. She develops septic shock twice. Each time, the medical team manages to bring her back.

After two months in the hospital, she is discharged to a rehabilitation facility. She has lost 40 pounds. She cannot walk unassisted. She will need dialysis for the rest of her life because her kidneys never recovered. She will never hold her grandchildren without fear of transmitting the resistant organism she now carries.

She went into the hospital for a gallstone. She came out with permanent kidney failure, months of hospitalization, and a drug-resistant organism colonizing her body.

This is what the Olympus duodenoscope litigation is about. Not abstract statistics. Not regulatory acronyms. Human beings whose lives were destroyed by a device that the manufacturer knew was defective.

Why These Cases Matter

Medical device litigation is sometimes criticized as a tax on innovation, a drag on companies that are trying to develop life-saving technologies. That criticism misses the point of cases like this one.

Olympus did not face lawsuits because it made an honest mistake or because medicine is inherently uncertain. Olympus faced lawsuits because it designed a device that could not be cleaned, learned that patients were dying, and chose to protect its market share rather than fix the problem or warn the people at risk.

Litigation is the accountability mechanism when regulatory agencies fail and when corporations prioritize profits over patient safety. It is how victims obtain compensation for harms that were inflicted on them through no fault of their own. And it is how the legal system sends a message to every other medical device manufacturer: you cannot hide what you know and escape the consequences.

The Olympus duodenoscope cases are not just about the patients who were infected. They are about what kind of system we want. Do we want a system in which companies can sell defective devices, ignore contamination reports, delay warnings, and face no meaningful consequences? Or do we want a system in which corporate knowledge of danger triggers corporate responsibility to act?

These lawsuits are one way of answering that question.

Contact Us About an Olympus Duodenoscope Claim

If you or a family member developed a serious infection after an ERCP or other procedure involving an Olympus duodenoscope, you may have a claim. Our attorneys have experience handling complex medical device litigation and can evaluate your case at no cost.

Call us at 800-553-8082 or contact us online for a free consultation. There is no fee unless we recover compensation for you.